Yervoy (ipilimumab) is a monoclonal antibody that is used to treat advanced melanoma. It works by blocking the activity of a protein called CTLA-4, which helps to activate the immune system to fight cancer cells [1].

Although Yervoy is an effective treatment for melanoma, it can also cause side effects, especially when taken in high doses. The most common side effects of Yervoy include fatigue, diarrhea, skin rash, and itching [2]. However, there are also potential long-term side effects that patients should be aware of.

According to a study published in the Journal of Clinical Oncology, patients who received Yervoy had a higher risk of developing autoimmune disorders such as colitis, hepatitis, and hypophysitis. These disorders can occur months or even years after treatment with Yervoy has ended [3]. Another study published in the Journal of the American Medical Association found that patients who received Yervoy had a higher risk of developing thyroid disorders and adrenal insufficiency [4].

It is important to note that these long-term side effects are relatively rare, and most patients do not experience them. However, patients who are receiving Yervoy should be monitored closely for any signs of autoimmune disorders or other long-term side effects. If any symptoms do occur, patients should contact their healthcare provider immediately.

In conclusion, Yervoy is an effective treatment for advanced melanoma, but it can also cause side effects, including rare long-term side effects such as autoimmune disorders, thyroid disorders, and adrenal insufficiency. Patients who are receiving Yervoy should be monitored closely for any signs of these side effects and should contact their healthcare provider immediately if any symptoms occur.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504411/
[4] https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects